A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

123 adults with type 1 diabetes were randomly assigned to technosphere insulin plus insulin degludec (Tresiba, Novo Nordisk) with use of a Dexcom G7 continuous glucose monitor, or usual care with ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

while insulin glargine and insulin degludec have side effects that mean some patients are unable to take them. Novo Nordisk has been selling Levemir in the US for nearly 20 years, and in March ...

The new medicine (branded as Ryzodeg) is a combination of two other medicines: insulin degludec (an ultra-long-acting insulin) and insulin aspart (a rapid-acting insulin). If the funding proposal ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar level lowering effect. Rapid-acting insulin called insulin aspart - this lowers ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar lowering effect. Rapid acting insulin called insulin aspart - this lowers your ...

including long-acting insulin degludec, rapid-acting insulin aspart, and premix insulin preparations including the combination of insulin degludec and aspart. To improve the convenience of our ...